Case Study | October 02, 2008 | Suhny Abbara, M.D., assistant professor, Harvard Medical School, director, Cardiovascular Imaging, M
Stock image

This case is a routine coronary CTA with the focus on the coronary arteries. The patient was a middle-aged male with a family history of coronary artery disease, moderate risk profile and atypical chest pain. The EKG did not indicate myocardial ischemia and there was no enzyme leak. The referring physician was considering invasive angiography to definitely exclude coronary artery disease as the cause of the atypical chest pain. Due to concerns regarding the invasiveness of the procedure and a relatively low likelihood that coronary artery disease was present, a cardiac gated 64-slice coronary MDCT angiogram was performed instead.
The contrast injection protocol in this study is tailored to opacify the coronary arteries during the MDCT acquisition and to wash out the right atrium and ventricle with a saline chaser bolus.
The latter is desired for two reasons. First, if contrast were to remain in the right heart during acquisition, streak artifact may result in image degradation, potentially decreasing the evaluability of the mid-RCA. The streak artifact occurs because of the mixing of relatively dense contrast containing blood from the superior vena cava with in-flowing, non-opacified blood from the inferior vena cava. Secondly, if contrast material is located in the right heart during the scan acquisition, it obviously cannot contribute to the opacification of the coronary arteries — the structures of interest. A higher contrast volume at a higher rate, therefore, would be necessary to achieve the same opacification as in a patient with washed out right heart and optimal contrast timing.
Because the image quality in this case is excellent and the negative predictive value of coronary CTA in research studies is typically between 95 and 100 percent, it could be established that in this patient the chest symptoms were unrelated to coronary artery disease. The patient was spared the invasive angiogram.


Related Content

News | Radiology Business

July 9, 2024 — Bracco and Blue Earth Diagnostics, a Bracco company and recognized leader in the development and ...

Time July 09, 2024
arrow
News | Contrast Media

May 8, 2024 — Swedish biotech company Ascelia Pharma AB has announced that its liver imaging drug candidate, Orviglance ...

Time May 08, 2024
arrow
News | FDA

April 18, 2024 — Lumicell, Inc., a privately held company focused on developing innovative fluorescence-guided imaging ...

Time April 18, 2024
arrow
News | Radiopharmaceuticals and Tracers

April 5, 2024 — RLS Radiopharmacies, America’s only Joint Commission-accredited radiopharmacy network, today announced ...

Time April 05, 2024
arrow
News | Molecular Imaging

March 29, 2024 — Magnetic resonance imaging (MRI) is a cornerstone in the landscape of medical diagnostics, celebrated ...

Time March 29, 2024
arrow
News | Breast Imaging

March 8, 2024 — Lumicell, Inc., a privately held company focused on innovative fluorescence-guided imaging technologies ...

Time March 08, 2024
arrow
News | SNMMI

February 6, 2024 — The Society of Nuclear Medicine and Molecular Imaging (SNMMI) held its 2024 SNMMI Mid-Winter Meeting ...

Time February 06, 2024
arrow
Feature | Contrast Media Injectors | By Christine Book

Contrast media injectors are used to inject contrast media or contrast agents to enhance the blood and perfusion in ...

Time January 17, 2024
arrow
News | Contrast Media

December 11, 2023 — Bracco Imaging S.p.A., an innovative world leader delivering end-to-end products and solutions ...

Time December 11, 2023
arrow
News | Interventional Radiology

November 3, 2023 — Guerbet, a global leader in medical imaging with more than 30 years of experience in MRI, announced ...

Time November 03, 2023
arrow
Subscribe Now